Get started
Author

Martin Leonhard Heubner

Observed names: M HEUBNER, M Heubner, M. Heubner, M. L. Heubner, M.L. Heubner, MARTIN HEUBNER, Martin Heubner, Martin L. Heubner, MartinLeonhard Heubner
Institution: Kantonsspital Baden
Observed institutions: The Wistar Institute, University of Zurich, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe, Essen University Hospital, Kantonsspital Baden, Deutsches Konsortium für Translationale Krebsforschung, German Cancer Consortium (DKTK) Dresden, Stiftung Universitätsmedizin Essen, University of Duisburg-Essen, Pomeranian Medical University
ORCID: 0000-0002-2715-3387
Observed ORCID: 0000-0002-2715-3387
OpenAlex ID: A5077980510
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
2015 · Andreas du Bois, Gunnar Kristensen, et al. · The Lancet Oncology · 218
PDF
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
2020 · Jacobus Pfisterer, Catherine M Shannon, et al. · The Lancet Oncology · 179
PDF
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
2024 · Nicoletta Colombo, Elena Biagioli, et al. · The Lancet Oncology · 156
Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results
2015 · Johannes Grueneisen, Benedikt Michael Schaarschmidt, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 107
Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy
2011 · Bahriye Aktas, Sabine Kasimir-Bauer, et al. · International Journal of Gynecological Cancer · 107
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
2019 · Ignace Vergote, Giovanni Scambia, et al. · The Lancet Oncology · 94
PDF
Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT
2015 · Johannes Grueneisen, Benedikt Michael Schaarschmidt, et al. · European Journal of Radiology · 88
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
2015 · Günter Emons, Christian Kurzeder, et al. · Gynecologic Oncology · 75
Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis
2014 · Johannes Grueneisen, Karsten Beiderwellen, et al. · Investigative Radiology · 69
Diagnostic Value of Diffusion-Weighted Imaging in Simultaneous 18F-FDG PET/MR Imaging for Whole-Body Staging of Women with Pelvic Malignancies
2014 · Johannes Grueneisen, Benedikt Michael Schaarschmidt, et al. · Journal of Nuclear Medicine · 67
PDF
Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer
2007 · P WIMBERGER, M HEUBNER, et al. · Gynecologic Oncology · 56
p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group
2021 · Linn Woelber, Katharina Prieske, et al. · American Journal of Obstetrics and Gynecology · 48
PDF
Morbidity of Inguinofemoral Lymphadenectomy in Vulval Cancer
2012 · A. A. Soliman, M. Heubner, et al. · The Scientific World JOURNAL · 46
PDF
The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer
2010 · Martin Heubner, Pauline Wimberger, et al. · Gynecologic Oncology · 46
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
2022 · Jacobus Pfisterer, Florence Joly, et al. · Journal of Clinical Oncology · 43
Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanine‐green (ICG)
2016 · Rainer Kimmig, Bahriye Aktas, et al. · Journal of Surgical Oncology · 39
PDF
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al. · Clinical Cancer Research · 34
PDF
Suspensory Ligaments of the Female Genital Organs: MRI Evaluation with Intraoperative Correlation
2018 · Malwina Kaniewska, Piotr Gołofit, et al. · Radiographics · 34
PDF
Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as ‘total mesometrial resection (TMMR)’ by M Höckel translated to robotic surgery (rTMMR)
2013 · Rainer Kimmig, Pauline Wimberger, et al. · World Journal of Surgical Oncology · 34
PDF
Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M Höckel translated to robotic surgery
2013 · Rainer Kimmig, Bahriye Aktas, et al. · World Journal of Surgical Oncology · 33
PDF
Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
2011 · Oliver Hoffmann, Bahriye Aktas, et al. · PubMed · 32
B3-lesions of the breast and cancer risk - an analysis of mammography screening patients
2016 · OLIVER HOFFMANN, GESINA ATHINA STAMATIS, et al. · Molecular and Clinical Oncology · 31
PDF
Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy
2015 · Rainer Kimmig, Antonella Iannaccone, et al. · Archives of Gynecology and Obstetrics · 30
PDF
Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.
2013 · Bahriye Aktas, Sabine Kasimir-Bauer, et al. · PubMed · 28
Circulating 20S proteasome in patients with non-metastasized breast cancer.
2011 · Oliver Hoffmann, Martin Heubner, et al. · PubMed · 26
Works count: 115
Citation count: 1,960
H-index: 25
I10-index: 33
Year
Topic
Type